Where the Street stands
These are third-party analyst opinions from named firms, not advice, and not a prediction. How we score this
22 firms currently rating it, weighted by track record.
The 22 firms with a track record here beat the S&P 40% of the time over 12 months.
Pro: see the crowd-vs-sharp split for UNHTwenty-six analysts rate UnitedHealth a buy or stronger, with an average price target of $475.23 implying 13.8% upside from current levels. JPMorgan, Morgan Stanley, and five other firms maintained overweight or outperform ratings in recent weeks, though Baird upgraded from underperform to neutral on July 16. The healthcare plans giant trades at a trailing P/E of 31.64 while posting 61.5% EPS growth year-over-year, a sharp acceleration from 0.4% revenue growth, and maintains a low-leverage balance sheet with 0.69 debt-to-equity.
Generated from the data on this page; may contain errors. Analyst opinions belong to the named firms. Informational only, not investment advice.
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jul 21, 2026 | JPMorgan | ○ Maintained | |
| Jul 21, 2026 | Mizuho | ○ Maintained |
Create a free account to unlock all analyst ratings, key stats, and news. No credit card, takes 30 seconds.
Sign up free